Cantor Fitzgerald Weighs in on Metsera FY2025 Earnings

Metsera, Inc. (NASDAQ:MTSR - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Metsera in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now expects that the company will earn ($3.58) per share for the year, down from their prior estimate of ($3.38). Cantor Fitzgerald currently has a "Overweight" rating on the stock.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Several other brokerages also recently weighed in on MTSR. Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "outperform" rating on the stock. Guggenheim began coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price objective on the stock. Finally, Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company.

Metsera Trading Down 6.7 %

NASDAQ:MTSR traded down $1.51 during midday trading on Monday, reaching $21.15. The stock had a trading volume of 1,500,143 shares, compared to its average volume of 708,601. Metsera has a 12-month low of $20.04 and a 12-month high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.